Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis DatabaseChangsu L Park, Ramy Saleh, Feras A. Moria et al.|Current Oncology|2024Cited by 9
Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.Ana-Alicia Beltran-Bless, Christina M. Canil, Jeffrey Graham et al.|Journal of Clinical Oncology|2024Cited by 2
Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.Carissa Beaulieu, Naveen S. Basappa, Sunita Ghosh et al.|Journal of Clinical Oncology|2024Cited by 1
Comparison of patients with high-risk nonmetastatic clear cell renal carcinoma in adjuvant therapy trials versus nonclinical trial patients.Jen Hoogenes, Anil Kapoor, Rodney H. Breau et al.|Journal of Clinical Oncology|2022Cited by 1
Impact of timing of immunotherapy and cytoreductive nephrectomy on outcomes in metastatic renal cell carcinoma: Results from the CKCis database.Changsu Park, Ramy Saleh, Sunita Ghosh et al.|Journal of Clinical Oncology|2024Cited by 0